Lipid-Lowering Agents - Czechia

Czechia

Highlights

The Lipid-Lowering Agents market in Czechia is set to experience significant growth in the coming years.
According to projections, the revenue in this market is expected to reach US$15.01m in 2024.
Furthermore, the market is anticipated to show a steady annual growth rate (CAGR 2024-2029) of 0.05%, leading to a market volume of US$15.05m by 2029.
When compared globally, it is worth noting that United States is expected to generate the highest revenue in the Lipid-Lowering Agents market.
In 2024, United States is projected to generate a revenue of US$4.46bn.
This highlights the significant market potential and importance of the Lipid-Lowering Agents market industry United States.
The demand for lipid-lowering agents in Czechia is on the rise due to an increasing awareness of the importance of cholesterol management among the population.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The demand for Lipid-Lowering Agents in Czechia has been steadily increasing over the years.

Customer preferences: Czechia has a high prevalence of cardiovascular diseases, which has led to an increased demand for Lipid-Lowering Agents. Additionally, there has been a growing awareness among the population about the importance of maintaining a healthy lifestyle, which has also contributed to the rising demand for these drugs.

Trends in the market: The Lipid-Lowering Agents market in Czechia is dominated by statins, which account for the majority of the market share. However, there has been a shift towards newer drugs such as PCSK9 inhibitors, which have shown promising results in reducing LDL cholesterol levels. This trend is expected to continue in the future as more clinical data becomes available.

Local special circumstances: One of the unique aspects of the Lipid-Lowering Agents market in Czechia is the high level of government intervention. The government regulates the prices of drugs, which has led to lower prices compared to other European countries. This has made the drugs more affordable for the general population, which has contributed to the increased demand.

Underlying macroeconomic factors: The Czech economy has been growing steadily over the years, which has led to an increase in disposable income among the population. This has made it easier for people to afford Lipid-Lowering Agents, which has contributed to the growth of the market. Additionally, the aging population in Czechia has led to an increase in the prevalence of cardiovascular diseases, which has also contributed to the growth of the market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.